Amivantamab

News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Amivantamab
Oct 5, 2024, 02:12 | Insight
Eric K. Singhi: FDA Oncology approves amivantamab and chemo for EGFR and NSCLC
Eric K. Singhi shared a post on X: “FDA Oncology approves amivantamab and chemo for…
Sep 24, 2024, 11:04 | Blog
Stephen V Liu: The recent FDA approval of the MARIPOSA-2 regimen for EGFR NSCLC
Stephen V Liu shared a post on X: ''In this episode of the IASLC podcast…
Sep 24, 2024, 00:05 | Blog
Rahul Gosain: Amivantamab and Chemo now FDA approved in 2L mEGFR NSCLC after Osimertinib
Rahul Gosain posted on LinkedIn: "Amivantamab and Chemo now FDA approved in 2L mEGFR NSCLC…
Sep 10, 2024, 13:45 | Societies
Rami Manochakian's key highlights from WCLC24
WCLC is a major international event focused on the latest advancements in lung cancer research,…
Sep 9, 2024, 09:55 | Societies
Insights from WCLC24 by Chul Kim
The WCLC24 is taking place at the San Diego Convention Center from September 7 to…
Sep 2, 2024, 09:38 | Insight
Antonio Passaro: EMA approves amivantamab in combination with chemo for treatment of advanced EGFR-mutated NSCLC after Osimertinib
Antonio Passaro, shared a post on X: "EMA approves amivantamab in combination with chemo for…
Aug 29, 2024, 17:43 | Insight
FDA’s latest approvals summarized by Samuel Hume
Samuel Hume, Researcher at the University of Oxford, recently shared on X: “The FDA approved 4…
Aug 29, 2024, 16:15 | Drugs
Antonio Passaro: European Commission approves amivantamab
Antonio Passaro shared on LinkedIn: "I'm proud to announce that, yesterday August 27, the European…
Aug 24, 2024, 11:47 | Insight
Narjust Florez: Discussion with Julia Rotow about the MARIPOSA trial
Narjust Florez shared a post by IASLC on X, adding: “At The International Association for…
Aug 24, 2024, 11:15 | Insight
Jill Feldman: Exciting news for the EGFR lung cancer community
Luis E. Raez, Medical Director at Memorial Cancer Institute, shared a post by Jill Feldman on…
Aug 23, 2024, 14:21 | Drugs
Stephen V Liu: How do we select the optimal regimen for EGFR NSCLC?
Stephen V Liu shared on X: "With FLAURA (osimertinib alone), FLAURA2 (osimertinib with chemotherapy), and…
Aug 22, 2024, 02:10 | Insight
Identifying approaches to reduce IRRs with IV amivantamab
Gilberto Lopes, Associate director for global oncology and interim chief for the Division of Medical…
Jul 1, 2024, 15:01 | Blog
Antonio Passaro: A significant milestone for the advancement and understanding of EGFR-mutated NSCLC
Antonio Passaro, shared a post on LinkedIn: "I am honored to have contributed, as investigator…
Jun 28, 2024, 11:08 | Insight
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results Authors: E. Felip, B.C.…
Jun 25, 2024, 16:15 | Career
Emrullah Yilmaz: Excited to join the amivantamab clinical team at Johnson and Johnson Innovative Medicine
Emrullah Yilmaz, Medical Director at Johnson & Johnson Innovative Medicine, shared on LinkedIn: "I’m happy…
Jun 21, 2024, 10:50 | Blog
Out in JCO the groundbreaking results of the randomized phase 3 trial PALOMA-3 study
Antonio Passaro, Medical Oncologist at the European Institute of Oncology, shared on LinkedIn: "Out in…
Jun 13, 2024, 15:48 | Insight
Stephen Liu on a paper by Natasha Leighl, et al.
Stephen Liu recently shared a post on X: "PALOMA-3 results at Journal of Clinical Oncology…
Jun 2, 2024, 09:09 | Societies
15 Posts From ASCO24 Day 2 You Should Not Miss!
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting is being held from May…
Jun 1, 2024, 12:55 | Societies
Day 1 ASCO24 Highlights by Oncology Brothers
Oncology Brothers shared on X: Day 1 ASCO24 Highlights: 1. CROWN: Lorlatinib in ALK mNSCLC…
Jun 1, 2024, 11:24 | Blog
Narjust Florez: It is not only about living longer but also living well for our patients
Narjust Florez shared a post by Shankar Siva, Professor, Faculty of Medicine at University of Melbourne on…
May 29, 2024, 12:03 | Insight
Eric Singhi: MARIPOSA a path forward to help us determine who benefits from 1L combination therapy?
Eric Singhi shared on X:  "MARIPOSA: Amivantamab + lazertinib v osimertinib in 1L EGFR+ mNSCLC:…
May 28, 2024, 08:21 | Blog
Antonio Passaro's top 10 selection with explanation, among the lung cancer abstracts from ASCO24
Antonio Passaro, shared a post on X: ''ASCO24 is ready to start soon! Here, my top…
May 27, 2024, 04:19 | Opinion
Gilberto Lopes: My top ASCO24 lung cancer abstracts!
Gilberto Lopes, Chief of the Division of Medical Oncology at Sylvester Comprehensive Cancer Center, shared…
May 23, 2024, 07:56 | Blog
Chinmay Jani: Let's explore EGFR Exon 20 Insertion NSCLC with a twist of Miami flair!
Chinmay Jani, Clinical Fellow, Hematology & Oncology at University of Miami, made the following post…
Mar 25, 2024, 15:15 | Societies
25 Posts Not To Miss From ELCC 2024
The European Lung Cancer Congress (ELCC 2024) took place in Prague, Czech Republic, from 20th…
Mar 6, 2024, 11:34 | Drugs
Rami Manochakian: U.S. FDA approves Amivantamab WITH CHEMOTHERAPY for 1st Line treatment of advanced non-small cell Lung Cancer with EGFR
Rami Manochakian, Hematology-Oncology Fellowship Director at Mayo Clinic, shared on X/Twitter: “HOT OFF THE PRESS…
Mar 5, 2024, 19:49 | Insight
Eric K. Singhi: Great to see this option approved for our patients with Exon 20 Group insertions
Eric K. Singhi, Thoracic Medical Oncologist and Assistant Professor at the MD Anderson Cancer Center,…
Jan 16, 2024, 05:48 | Drugs
Stephen V Liu: Many updates in the 1.2024 National Comprehensive Cancer Network (NCCN) NSCLC guidelines
Stephen V Liu, Director of Thoracic Oncology and Developmental Therapeutics at Lombardi Comprehensive Cancer Center,…
Jan 10, 2024, 18:21 | Blog
Top Precision Oncology articles of 2023 by Vivek Subbiah
Vivek Subbiah shared on X/Twitter: "By popular demand delighted to share the 'Top Precision Oncology…
Nov 28, 2023, 18:00 | Drugs
Stephen V Liu: Report on real world efficacy and safety of amivantamab including off label use
Stephen V Liu, Director of Thoracic Oncology and Developmental Therapeutics at the Lombardi Comprehensive Cancer…
Oct 29, 2023, 03:16 | Drugs
Antonio Passaro: I was honored to present in Presidential, the primary results of the global randomized phase 3 study MARIPOSA-2
Antonio Passaro, Medical Oncologist at the European Institute of Oncology, shared on LinkedIn: "ESMO23 is…
Oct 25, 2023, 19:02 | Insight
Amalya Sargsyan: ESMO23 - Advances in EGFR mutated NSCLC
Amalya Sargsyan, Research Fellow at Immune Oncology Research Institute, shared a post on LinkedIn: "ESMO23:…
May 14, 2023, 09:34 | Drugs
Amivantamab Shows Efficacy in Advanced NSCLC With EGFR Exon 20 Insertions - The ASCO Post
Quoting from ASCO Post, "Amivantamab-vmjw, an EGFR and MET bispecific monoclonal antibody, has demonstrated encouraging…
All: 33 Posts: 1 - 100
Special Coverage